1-[(2-fluorophenyl)methyl]-3-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyrazolo[3,4-b]pyridine | 1344669-78-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 1-[(2-fluorophenyl)methyl]-3-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyrazolo[3,4-b]pyridine
• CAS: 1344669-78-8
• 化学式: C₁₆H₁₀F₄N₆
• 分子量: 362.289
• InChiKey: MERGIIICASZYJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  72.3
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲腈 在 一水合肼 作用下， 以 甲醇 为溶剂， 生成 1-[(2-fluorophenyl)methyl]-3-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyrazolo[3,4-b]pyridine
  参考文献：
  名称：

  Acidic triazoles as soluble guanylate cyclase stimulators

  摘要：

  A series of acidic triazoles with activity as soluble guanylate cyclase stimulators is described. Incorporation of the CF(3) triazole improved the overall physicochemical and drug-like properties of the molecule and is exemplified by compound 25. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.071

文献信息

• SGC stimulators
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US11180493B2

  公开（公告）日：2021-11-23

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).

  本公开涉及可溶性鸟苷酸环化酶（sGC）的刺激剂、包含它们的药物制剂及其单独或与一种或多种附加制剂组合的用途，用于治疗各种疾病，其中一氧化氮（NO）浓度的增加和/或环磷酸鸟苷（cGMP）浓度的增加可能是可取的。本文公开了多种化合物，包括式（I）化合物。
• TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US20190343813A1

  公开（公告）日：2019-11-14

  The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′,5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
• SGC STIMULATORS
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US20200071318A1

  公开（公告）日：2020-03-05

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).
• USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US20210177846A1

  公开（公告）日：2021-06-17

  The present disclosure relates to methods, uses, pharmaceutical compositions comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a mitochondrial disorder.
• sGC STIMULATORS
  申请人：Cyclerion Therapeutics, Inc.

  公开号：US20220017515A1

  公开（公告）日：2022-01-20

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I: